RB101(S), a dual inhibitor of enkephalinases does not induce antinociceptive tolerance, or cross-tolerance with morphine: A c-Fos study at the spinal level

European Journal of Pharmacology

Volumn 441, Issue 3, 2002, Pages 141-150

  Guen, Stéphanie Le ^a   Noble, Florence ^a   Fournié Zaluski, Marie Claude ^a   Roques, Bernard Pierre ^a   Besson, Jean Marie ^b   Buritova, Jaroslava ^b  

^a CNRS   (France)

^b INSERM   (France)

Author keywords

c Fos; Carrageenin; Endogenous; Enkephalin; RB101; Spinal Cord; Tolerance

Indexed keywords

ANALGESIC AGENT; DISULFIDE; DRUG DERIVATIVE; ENKEPHALIN; ENZYME INHIBITOR; MORPHINE; N [3 [(2 AMINO 4 METHYLTHIO)BUTYLDITHIO] 2 BENZYLPROPIONYL]PHENYLALANINE BENZYL ESTER; PHENYLALANINE; PROTEIN C FOS; CARRAGEENAN; DRUG VEHICLE; MEMBRANE METALLOENDOPEPTIDASE;

ANIMAL; ARTICLE; BIOSYNTHESIS; CHEMISTRY; DRUG TOLERANCE; ENZYMOLOGY; MALE; METABOLISM; PHYSIOLOGY; RAT; SPINAL CORD; SPRAGUE DAWLEY RAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CROSS TOLERANCE; DRUG EFFECT; DRUG RESPONSE; DRUG SCREENING; ENANTIOMER; EVOKED SPINAL CORD RESPONSE; IMMUNOREACTIVITY; INFLAMMATION; LUMBAR SPINAL CORD; NOCICEPTIVE STIMULATION; NONHUMAN; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; SPINAL CORD STIMULATION;

ANALGESICS; ANIMALS; DISULFIDES; DRUG TOLERANCE; ENKEPHALINS; ENZYME INHIBITORS; MALE; MORPHINE; PHENYLALANINE; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD; ANIMAL; SUPPORT, NON-U.S. GOV'T;

EID: 0037177359     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)01497-2     Document Type: Article

References (55)

1. Effects of opioids and non-opioids on c-Fos immunoreactivity induced in rat lumbar spinal cord neurones by noxious heat stimulation
2. The many possible roles of opioids and related peptides in stress-induced analgesia
3. Endogenous opioids: Overview and current issues
4. Endogenous pain control systems: Brainstem spinal pathways and endorphin circuitry
5. Peripheral and spinal mechanisms of nociception
6. Intracerebroventricular morphine decreases descending inhibitions acting on lumbar dorsal horn neuronal activities related to pain in the rat
7. C-Fos protein expression in the dorsal horn of the spinal cord, a technique to study some physiopharmacological aspects of nociception
8. Interactions between NMDA- and prostaglandin receptor-mediated events in a model of inflammatory nociception
9. Enhanced effects of co-administered dexamethasone and diclofenac on inflammatory pain processing and spinal c-Fos expression in the rat: Synergistic mechanisms
10. Pharmacological studies of nociceptive systems using the c-Fos immunohistochemical technique: An indicator of noxiously activated spinal neurones
11. Cholecystokinin B receptor antagonism enhances the ability of a low dose of morphine to reduce c-Fos expression in the spinal cord of the rat
12. Tolerance and cross tolerance with morphine resulting from physiological release of endogenous opiates
13. Modification of morphine withdrawal by drugs interacting with humoral mechanisms: Some contradictions and their interpretation
14. Development of tolerance to endogenous opiates activated by 24-h food deprivation
15. Mixed-inhibitor-prodrug as a new approach towards systemically active inhibitors of enkephalin degrading enzymes
16. Time course of dependence and tolerance development in rats treated with 'slow release' morphine suspensions
17. Differential contribution of descending controls to the antinociceptive actions of kappa and mu opioids: An analysis of formalin-evoked c-Fos expression
18. Using c-fos as a neural marker of pain
19. Opiate tolerance and dependence: Receptors, G-proteins, and antiopiates
20. Carrageenin-evoked c-Fos expression in rat lumbar spinal cord: The effects of indomethacin
21. When is the maximal effect of pre-administered systemic morphine on carrageenin-evoked spinal c-Fos expression in the rat?
22. B receptor antagonist as revealed by noxiously-evoked spinal c-Fos expression in the rat
23. Chronic treatment with systemic morphine induced tolerance to the systemic and peripheral antinociceptive effects of morphine on both carrageenin induced mechanical hyperalgesia and spinal c-Fos expression in awake rats
24. Drug addiction and drug abuse
25. Mu-opioid receptor internalization: Opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain
26. Molecular mechanisms and regulation of opioid receptor signaling
27. Development of tolerance to the antinociceptive effect of systemic morphine at the lumbar spinal cord level: A c-Fos study in the rat
28. Effects of NMDA receptor antagonists on morphine tolerance: A c-Fos study in the lumbar spinal cord of the rat
29. The effects of RB101, a mixed inhibitor of enkephalin-catabolizing enzymes, on carrageenin-induced spinal c-Fos expression are completely blocked by beta-funaltrexamine, a selective mu-opioid receptor antagonist
30. Antinociceptive effects of RB101(S), a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by (+)-HA966, a functional NMDA antagonist: A c-Fos study in a model of inflammatory nociception in rats
31. RB101(S) does not induce tolerance, nor cross-tolerance with morphine
32. Opioid and non-opioid stress analgesia: Assessment of tolerance and cross-tolerance with morphine
33. Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation
34. Binding in vivo of selective μ and δ opioid receptor agonists
35. Analgesia and decrement in operant performance in socially defeated mice: Selective cross-tolerance to morphine and antagonism by naltrexone
36. Assessment of endogenous enkephalins efficacy in the hot plate test in mice: Comparative study with morphine
37. Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats
38. Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine
39. Isolation and expression of a novel alternatively spliced mu opioid receptor isoform, MOR-1F
40. Tolerance and cross-tolerance with morphine in mice selectively bred for high and low stress-induced analgesia
41. Systemic morphine suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in the rat spinal cord
42. The cytoarchitectonic organization of the spinal cord in the cat
43. Formalin-evoked Fos expression in spinal cord is enhanced in morphine-tolerant rats
44. Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology
45. 3H]diprenorphine binding
46. Endomorphin-1 and endomorphin-2 show differences in their activation of mu opioid receptor-regulated G proteins in supraspinal antinociception in mice
47. Electrophysiological studies on the spinal role of endogenous opioids in carrageenin inflammation
48. Cholecystokinin and morphine analgesia: Variations on a theme
49. Effects of Kelatorphan and morphine before and after noxious stimulation on immediate-early gene expression in rat spinal cord neurones
50. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins
51. B receptor antagonist
52. Carrageenan-induced oedema in hind paw of the rat as an assay for antiinflammatory drugs
53. Stress-induced behavioural responses and multiple opioid systems in the brain
54. Ethical guidelines for investigations of experimental pain in conscious animals